

## 510(k) Summary

| Applicant's name and address                      | Heraeus Kulzer GmbH & Co. KG                              |
|---------------------------------------------------|-----------------------------------------------------------|
|                                                   | Grüner Weg 11                                             |
|                                                   | D-63450 Hanau                                             |
| Contact persons                                   | Dr. KD. Kühn                                              |
| *                                                 | phone: +49 6081 959-264                                   |
|                                                   | fax: +49 6081 959-288                                     |
|                                                   | klaus-dieter.kuehn@heraeus.com                            |
|                                                   | Dr. C. Tuchscherer                                        |
|                                                   | phone: +49 6081 959-278                                   |
|                                                   | fax: +49 6081 959-288                                     |
|                                                   | christian.tuchscherer@heraeus.com                         |
| Date of summary                                   | March 19 <sup>th</sup> , 2003                             |
| Device trade name                                 | PALAMED®                                                  |
| Classification name                               | Bone Cement                                               |
| Identification of the marketed device Palamed® to | PALAMED <sup>®</sup>                                      |
| which equivalence is claimed                      | 510k (Merck) K010586                                      |
| Description of the device                         | Palamed <sup>®</sup> is an acrylic bone cement for use in |
|                                                   | orthopedic surgery. It is formed from powder and          |
|                                                   | liquid by exothermic polymerization. It secures the       |
|                                                   | fixation of the grafted artificial joint improving the    |
|                                                   | transfer of forces at the interface implant - bone.       |
| Intended use                                      | Fixation of prostheses in the bone (partial or total      |
|                                                   | hip joint replacement at the hip, knee or other           |
|                                                   | joints).                                                  |
| Comparison of technological characteristics       | This is the already known Palamed® marketed by            |
|                                                   | Merck.                                                    |







SEP 2 3 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Dr. K. D. Kühn Head of Department Heraeus Kulzer GmbH & Co. KG Grüner Weg 11 Hanau, Germany D-63450

Re: K030904

Trade/Device Name: PALAMED® Regulation Number: 21 CFR 888.3027

Regulation Name: Polymethylmethacrylate (PMMA) bone cement

Regulatory Class: II Product Code: LOD Dated: June 25, 2003 Received: July 14, 2003

Dear Dr. Kühn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

| Abbreviated 510(k)   |    |
|----------------------|----|
| Palamed <sup>®</sup> | HE |

## **Intended Use**

Palamed\* is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.

(Division Sign-Off)
Division of General, Restorative and Neurological Devices

510(k) Number <u>K030904</u>